JNJ

188.37

-0.71%↓

ABT

128.3

+1.91%↑

MDT

94.2

+0.53%↑

VEEV

296.28

+0.2%↑

A

146.93

+0.09%↑

JNJ

188.37

-0.71%↓

ABT

128.3

+1.91%↑

MDT

94.2

+0.53%↑

VEEV

296.28

+0.2%↑

A

146.93

+0.09%↑

JNJ

188.37

-0.71%↓

ABT

128.3

+1.91%↑

MDT

94.2

+0.53%↑

VEEV

296.28

+0.2%↑

A

146.93

+0.09%↑

JNJ

188.37

-0.71%↓

ABT

128.3

+1.91%↑

MDT

94.2

+0.53%↑

VEEV

296.28

+0.2%↑

A

146.93

+0.09%↑

JNJ

188.37

-0.71%↓

ABT

128.3

+1.91%↑

MDT

94.2

+0.53%↑

VEEV

296.28

+0.2%↑

A

146.93

+0.09%↑

Search

Aurinia Pharmaceuticals Inc

Abierto

SectorSalud

12.28 0.49

Resumen

Variación precio

24h

Actual

Mínimo

12.07

Máximo

12.57

Métricas clave

By Trading Economics

Ingresos

-1.8M

22M

Ventas

7.5M

70M

P/B

Media del Sector

27.535

37.461

Margen de beneficio

30.729

Empleados

130

EBITDA

6.3M

28M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

-1.85% downside

Dividendos

By Dow Jones

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

357M

1.6B

Apertura anterior

11.79

Cierre anterior

12.28

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

163 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Aurinia Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

27 oct 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

CSL Delays Flu-Vaccine Spinoff, Cuts Guidance As U.S. Vaccination Rates Decline

27 oct 2025, 23:00 UTC

Adquisiciones, fusiones, absorciones

Australia's AUB Opens Books to EQT After Receiving $3.44 Billion Takeover Offer

27 oct 2025, 21:42 UTC

Ganancias

Waste Management 3Q Revenue Climbs, Sees Fiscal Year Revenue at Low End of Prior View

27 oct 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Easing U.S.-China Trade Tensions -- Market Talk

27 oct 2025, 23:42 UTC

Charlas de Mercado

Gold Rises on Likely Technical Recovery -- Market Talk

27 oct 2025, 23:37 UTC

Charlas de Mercado

Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk

27 oct 2025, 23:00 UTC

Ganancias

The Good Vibes Are Back on Wall Street -- WSJ

27 oct 2025, 22:45 UTC

Adquisiciones, fusiones, absorciones

Australia's AUB Opens Books to EQT After Receiving $3.44B Takeover Offer

27 oct 2025, 22:06 UTC

Charlas de Mercado
Ganancias

Nucor Expects Weaker Steel Market in 4Q -- Market Talk

27 oct 2025, 22:05 UTC

Ganancias

China Southern Airlines: Continued Improvements in Business Environment Supported Results >1055.HK

27 oct 2025, 22:04 UTC

Ganancias

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 oct 2025, 22:04 UTC

Ganancias

China Southern Airlines 3Q Net CNY3.84B, Up 20.3% on Year >1055.HK

27 oct 2025, 22:03 UTC

Ganancias

China Southern Airlines 3Q Rev CNY51.37B, Up 3.0% on Year >1055.HK

27 oct 2025, 21:27 UTC

Ganancias

Waste Management 3Q Rev Climbs, Sees FY Rev at Low End of Prior View

27 oct 2025, 21:19 UTC

Ganancias

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 oct 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

27 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

27 oct 2025, 20:37 UTC

Ganancias

Waste Management: Decrease From Prior Rev Expectations Is Primarily Related to Further Decline in Recycled Commodity Pricing, Modestly Lower Rev Expectations From Healthcare Solutions >WM

27 oct 2025, 20:37 UTC

Ganancias

Waste Management: 2025 Free Cash Flow Guidance Remains Between $2.8B and $2.9B >WM

27 oct 2025, 20:37 UTC

Ganancias

Waste Management: 2025 Total Co Rev Is Now Expected Approximately $25.275B >WM

27 oct 2025, 20:37 UTC

Ganancias

Waste Management: Affirming 2025 Adjusted Operating EBITDA Guidance Between $7.475B and $7.625B >WM

27 oct 2025, 20:31 UTC

Ganancias

Nucor Sees 4Q Earnings Lower Than 3Q

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q Steel Mills Total Shipments 6.43M Tons >NUE

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q EPS $2.63 >NUE

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q Net $607M >NUE

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q Sales $8.52B >NUE

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q Total Tons Shipped to Outside Customers Down 1% >NUE

27 oct 2025, 20:30 UTC

Ganancias

Waste Management 3Q Adj EPS $1.98 >WM

27 oct 2025, 20:30 UTC

Ganancias

Waste Management 3Q Rev $6.44B >WM

27 oct 2025, 20:30 UTC

Ganancias

Waste Management 3Q Net $603M >WM

Comparación entre iguales

Cambio de precio

Aurinia Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

-1.85% caída

Estimación a 12 meses

Media 11.67 USD  -1.85%

Máximo 17 USD

Mínimo 9 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Aurinia Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

5

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.1 / 8.21Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

163 / 373 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
help-icon Live chat